MedWatch

Zealand’s SBS drug shows promising phase II results

Zealand Pharma’s candidate drug glepaglutide has met the primary endpoint in a phase II study testing it as a treatment of short bowel syndrome (SBS). Phase III trials can begin next year.

Photo: Zealand Pharma PR

Log in to read our articles

Welcome to MedWatch. A part of our content is exclusive and reserved for our users.

Try us for 14 days

Try a trial subscription for access to our quality journalism

Frontpage right now

Græske politikere skal undersøges i Novartis-sag

Det græske parlament har besluttet at nedsætte et særligt udvalg, der skal undersøge politikernes rolle i den påståede Novartis-skandale. Novartis’ græske direktør betvivler, at den overhovedet har fundet sted.

Related articles